Galapagos NV has achieved a late stage discovery milestone for small molecules against a novel target in the osteoarthritis (OA) alliance with Servier. As a result, Galapagos will receive approximately $4 million.   The two companies entered the alliance in July 2010 to develop new oral OA medicines. Galapagos is responsible for the discovery and development of new candidates and Servier has an exclusive option to license these candidates following Phase I trials. Galapagos is eligible to receiv...